Dr. Collinson is a partner at Forward Ventures. Previously he was Chairman, Chief Executive Officer and President of Aurora Biosciences Corporation (acquired by Vertex Pharmaceuticals Inc. for $600 million). Before Aurora, Dr. Collinson was Chief Executive Officer of privately held Andaris Limited (acquired by Quadrant plc, now part of Elan Corporation PLC). He held senior management positions at GlaxoWellcome PLC (now GlaxoSmithKline PLC) and Baxter International Inc., and was a consultant with The Boston Consulting Group.

Dr. Collinson is a director of Affinium Pharmaceuticals Inc., Asteres Inc., Essentialis Inc., Sequel Pharmaceuticals Inc., Tioga Pharmaceuticals Inc. and Vertex Pharmaceuticals Inc.

Dr. Collinson was previously a director of Cabrellis Pharmaceuticals Inc. (acquired by Pharmion, now part of Celgene Corporation), Conforma Therapeutics Corporation (acquired by BiogenIdec), GeneOhm Sciences (acquired by Becton Dickinson), NovaCardia Inc. (acquired by Merck & Co.), and Proprius Pharmaceuticals (acquired by Cypress Bioscience).

Dr. Collinson was awarded an MBA from Harvard Business School and a Ph.D. in Physical Chemistry from the University of Oxford.